S2k-Leitlinie Neuroendokrine Tumore
Standard
S2k-Leitlinie Neuroendokrine Tumore. / Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
In: Z GASTROENTEROL, Vol. 56, No. 6, 06.2018, p. 583-681.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - S2k-Leitlinie Neuroendokrine Tumore
AU - Schrader, Jörg
AU - Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
N1 - Leitlinie
PY - 2018/6
Y1 - 2018/6
N2 - This guideline was created for the first time and is intended as a practical aid for the diagnosis and therapy of neuroendocrine tumors. The aim is to represent the current state of science, promote the recognition of the disease and improve the treatment of patients. The guideline was created under the leadership of the DGVS and with participation of neighbouring scientific societies.
AB - This guideline was created for the first time and is intended as a practical aid for the diagnosis and therapy of neuroendocrine tumors. The aim is to represent the current state of science, promote the recognition of the disease and improve the treatment of patients. The guideline was created under the leadership of the DGVS and with participation of neighbouring scientific societies.
KW - English Abstract
KW - Journal Article
U2 - 10.1055/a-0604-2924
DO - 10.1055/a-0604-2924
M3 - Andere (Vorworte u.ä.)
C2 - 29890561
VL - 56
SP - 583
EP - 681
JO - Z GASTROENTEROL
JF - Z GASTROENTEROL
SN - 0044-2771
IS - 6
ER -